These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 15985213)

  • 1. [Partnership between academic research and industry to study a new anti-osteoporotic drug].
    Mentaverri R; Wattel A; Lemaire-Hurtel AS; Kamel S; Blesius A; Brazier M
    Med Sci (Paris); 2005; 21(6-7):663-8. PubMed ID: 15985213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Strontium ranelate: a novel concept for the treatment of osteoporosis].
    Dimai HP
    Wien Klin Wochenschr; 2005 Nov; 117(21-22):728-38. PubMed ID: 16416353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strontium signaling: molecular mechanisms and therapeutic implications in osteoporosis.
    Saidak Z; Marie PJ
    Pharmacol Ther; 2012 Nov; 136(2):216-26. PubMed ID: 22820094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of osteoclast mediated bone resorption--rationale for the design of new therapeutics.
    Väänänen K
    Adv Drug Deliv Rev; 2005 May; 57(7):959-71. PubMed ID: 15876398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro.
    Bonnelye E; Chabadel A; Saltel F; Jurdic P
    Bone; 2008 Jan; 42(1):129-38. PubMed ID: 17945546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strontium ranelate: a physiological approach for optimizing bone formation and resorption.
    Marie PJ
    Bone; 2006 Feb; 38(2 Suppl 1):S10-4. PubMed ID: 16439191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S 12911-2 inhibits osteoclastic bone resorption in vitro.
    Takahashi N; Sasaki T; Tsouderos Y; Suda T
    J Bone Miner Res; 2003 Jun; 18(6):1082-7. PubMed ID: 12817762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strontium as therapy for osteoporosis.
    Marie PJ
    Curr Opin Pharmacol; 2005 Dec; 5(6):633-6. PubMed ID: 16183330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation.
    Marie PJ
    Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S11-5. PubMed ID: 16735840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High extracellular calcium stimulates osteoclast-like cell formation and bone-resorbing activity in the presence of osteoblastic cells.
    Kaji H; Sugimoto T; Kanatani M; Chihara K
    J Bone Miner Res; 1996 Jul; 11(7):912-20. PubMed ID: 8797111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Calcium-sensing Receptor (CaR) is involved in strontium ranelate-induced osteoblast differentiation and mineralization.
    Takaoka S; Yamaguchi T; Yano S; Yamauchi M; Sugimoto T
    Horm Metab Res; 2010 Aug; 42(9):627-31. PubMed ID: 20560105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats.
    Ammann P; Shen V; Robin B; Mauras Y; Bonjour JP; Rizzoli R
    J Bone Miner Res; 2004 Dec; 19(12):2012-20. PubMed ID: 15537445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of bone resorption and osteoclast survival by nitric oxide: possible involvement of NMDA-receptor.
    Mentaverri R; Kamel S; Wattel A; Prouillet C; Sevenet N; Petit JP; Tordjmann T; Brazier M
    J Cell Biochem; 2003 Apr; 88(6):1145-56. PubMed ID: 12647297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Divalent cations mimic the inhibitory effect of extracellular ionised calcium on bone resorption by isolated rat osteoclasts: further evidence for a "calcium receptor".
    Zaidi M; Kerby J; Huang CL; Alam T; Rathod H; Chambers TJ; Moonga BS
    J Cell Physiol; 1991 Dec; 149(3):422-7. PubMed ID: 1660481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement in bone strength parameters. The role of strontium ranelate.
    Tournis S
    J Musculoskelet Neuronal Interact; 2007; 7(3):266-7. PubMed ID: 17947810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic agents for disorders of bone and calcium metabolism. Osteoporotic fracture prevention by strontium ranelate].
    Nakamura T
    Clin Calcium; 2007 Jan; 17(1):80-7. PubMed ID: 17211097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strontium ranelate decreases receptor activator of nuclear factor-ΚB ligand-induced osteoclastic differentiation in vitro: involvement of the calcium-sensing receptor.
    Caudrillier A; Hurtel-Lemaire AS; Wattel A; Cournarie F; Godin C; Petit L; Petit JP; Terwilliger E; Kamel S; Brown EM; Mentaverri R; Brazier M
    Mol Pharmacol; 2010 Oct; 78(4):569-76. PubMed ID: 20584969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mineralization of bone tissue: a forgotten dimension in osteoporosis research.
    Boivin G; Meunier PJ
    Osteoporos Int; 2003; 14 Suppl 3():S19-24. PubMed ID: 12730799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Strontium ranelate's (Osseor) dual mode of action: increasing bone mass and decreasing bone resorption].
    Kaliterna DM
    Reumatizam; 2008; 55(2):73-4. PubMed ID: 19024281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strontium ranelate in osteoporosis and beyond: identifying molecular targets in bone cell biology.
    Marie PJ
    Mol Interv; 2010 Oct; 10(5):305-12. PubMed ID: 21045244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.